natgillin/translations-raw huggingface dataset:
Leflunomide ratiopharm treatment should be started and supervised by a specialist who has experience in the treatment of rheumatoid arthritis and psoriatic arthritis. 
Zdravljenje z zdravilom Leflunomide ratiopharm mora uvesti in nadzorovati zdravnik specialist, ki ima izkušnje z zdravljenjem revmatoidnega artritisa in psoriatičnega artritisa.
It reduces inflammation by reducing the production of immune cells called ‘lymphocytes', which are responsible for inflammation. 
Zdravilo zmanjšuje vnetje tako, da zmanjša tvorjenje imunskih celic, imenovanih „limfociti“, ki so vzrok za vnetje.
The CHMP concluded that, in accordance with EU requirements, Leflunomide ratiopharm has been shown to have comparable quality and to be bioequivalent to Arava. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Leflunomide ratiopharm primerljivo raven kakovosti kot zdravilo Arava ter da mu je biološko enakovredno.
Therefore, the CHMP's view was that, as for Arava, the benefit outweighs the identified risk. 
Zato je menil, da njegove koristi, tako kot pri zdravilu Arava, odtehtajo znana tveganja.
What are the benefits and risks of Leflunomide ratiopharm? 
Kakšne so koristi in tveganja, povezani z zdravilom Leflunomide ratiopharm?
Because Leflunomide ratiopharm is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Arava. 
Ker je zdravilo Leflunomide ratiopharm generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Arava.
Leflunomide ratiopharm is a ‘generic medicine'. 
Leflunomide ratiopharm je „generično zdravilo“.
The Committee recommended that Leflunomide ratiopharm be given marketing authorisation. 
Priporočil je, da se za zdravilo Leflunomide ratiopharm izda dovoljenje za promet.
Leflunomide ratiopharm is a medicine that contains the active substance leflunomide. 
Leflunomide ratiopharm je zdravilo, ki vsebuje zdravilno učinkovino leflunomid.
Other information about Leflunomide ratiopharm 
Druge informacije o zdravilu Leflunomide ratiopharm
The active substance in Leflunomide ratiopharm, leflunomide, is an immunosuppressant. 
Zdravilna učinkovina zdravila Leflunomide ratiopharm, leflunomid, je zdravilo za zaviranje imunske odzivnosti.
Why has Leflunomide ratiopharm been approved? 
Zakaj je bilo zdravilo Leflunomide ratiopharm odobreno?
How has Leflunomide ratiopharm been studied? 
Kako je bilo zdravilo Leflunomide ratiopharm raziskano?
How is Leflunomide ratiopharm used? 
Kako se zdravilo Leflunomide ratiopharm uporablja?
What is Leflunomide ratiopharm used for? 
Za kaj se zdravilo Leflunomide ratiopharm uporablja?
What is Leflunomide ratiopharm? 
Kaj je zdravilo Leflunomide ratiopharm?
How does Leflunomide ratiopharm work? 
Kako zdravilo Leflunomide ratiopharm deluje?
The name of the medicine was changed to Adcirca on 21 October 2009. 
Ime zdravila je bilo 21. oktobra 2009 spremenjeno v Adcirca.
What measures are being taken to ensure the safe and effective use of Adcirca? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Adcirca?
What benefit has Adcirca shown during the studies? 
Kakšne koristi je zdravilo Adcirca izkazalo med študijami?
Before treatment, the patients could walk an average of 343 metres in six minutes. 
Pred zdravljenjem so bolniki v šestih minutah povprečno lahko prehodili 343 metrov.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom necessary depending on the patient's response. 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom potrebi lahko poveča glede na njihov odziv.
Previously known as Tadalafil Lilly. 
Prej znano kot Tadalafil Lilly.
The full EPAR for Adcirca can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Adcirca je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The European Commission granted a marketing authorisation valid throughout the EU for Tadalafil Lilly on 1 October 2008. 
Evropska komisija je dovoljenje za promet z zdravilom Tadalafil Lilly, veljavno po vsej Evropski uniji, izdala 1. oktobra 2008.
Other information about Adcirca 
Druge informacije o zdravilu Adcirca
Adcirca is taken as two tablets (40 mg) once a day, with or without food. 
Zdravilo se jemlje v odmerku dveh tablet (40 mg) enkrat na dan s hrano ali brez nje.
The main measure of effectiveness was the change in exercise capacity (the ability to carry out physical activity) measured by the distance the patients could walk in six minutes after 16 weeks of treatment. 
Glavno merilo učinkovitosti je bilo izboljšanje telesne zmogljivosti (sposobnosti opravljanja telesne dejavnosti), izmerjeno na podlagi razdalje, ki so jo bolniki lahko prehodili v šestih minutah po 16 tednih zdravljenja.
What is the risk associated with Adcirca? 
Kakšna tveganja so povezana z zdravilom Adcirca?
The ‘class' reflects the seriousness of the disease: ‘class II' involves slight limitation of physical activity and ‘class III' involves marked limitation of physical activity. 
Razred odraža resnost bolezni: razred II pomeni rahlo omejitev telesne zmogljivosti, razred III pa znatno omejitev telesne zmogljivosti.
Adcirca is used in patients with class II or III disease. 
Zdravilo se uporablja pri bolnikih z boleznijo razreda II ali III.
The CHMP decided that Adcirca's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Adcirca večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
A risk management plan has been developed to ensure that Adcirca is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Adcirca je bil pripravljen načrt obvladovanja tveganj.
Adcirca was more effective than placebo at improving exercise capacity. 
Zdravilo Adcirca je bilo pri izboljšanju telesne zmogljivosti učinkovitejše od placeba.
This authorisation was based on the authorisation granted to Cialis in 2002 (‘informed consent'). 
Izdaja tega dovoljenja je temeljila na dovoljenju za promet z zdravilom Cialis, ki je bilo izdano leta 2002 (uporaba dokumentacije s soglasjem).
After 16 weeks, this distance had increased by 26 metres more in the patients taking 40 mg Adcirca than in the patients taking placebo. 
Po 16 tednih se je pri bolnikih, ki so jemali 40-miligramski odmerek zdravila Adcirca, ta razdalja povečala za 26 metrov več kot pri tistih, ki so jemali placebo.
The most common side effects with Adcirca (seen in more than 1 patient in 10) are headache, flushing (reddening of the skin), nasopharyngitis (inflammation of the nose and throat) including a blocked or runny nose and blocked sinuses, nausea (feeling sick), dyspepsia (heartburn) including stomach ache, myalgia (muscle pain), back pain and pain in the extremities (arms, hands, legs and feet). 
Najpogostejši neželeni učinki zdravila Adcirca (opaženi pri več kot 1 bolniku od 10) so glavobol, zardevanje (pordelost kože), nazofaringitis (vnetje nosu in grla), vključno z zamašenim nosom ali izcedkom iz nosu in zamašenimi sinusi, navzeja (slabost), dispepsija (zgaga), vključno z bolečinami v želodcu, mialgija (bolečine v mišicah), bolečine v hrbtu in okončinah (rokah, dlaneh, nogah in stopalih).
For more information about treatment with Adcirca, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Adcirca preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Adcirca is a medicine that contains the active substance tadalafil. 
Adcirca je zdravilo, ki vsebuje zdravilno učinkovino tadalafil.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Adcirca, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
This is a summary of the European public assessment report (EPAR) for Adcirca. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Adcirca.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Adcirca. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Adcirca is not recommended for patients with severe kidney or liver problems. 
Zdravilo Adcirca ni priporočeno za bolnike z resnimi težavami z ledvicami ali jetri.
Adcirca is used to treat adults with pulmonary arterial hypertension (PAH) to improve exercise capacity (the ability to carry out physical activity). 
Zdravilo Adcirca se uporablja za zdravljenje odraslih bolnikov s pljučno arterijsko hipertenzijo (PAH) za izboljšanje telesne zmogljivosti (sposobnosti izvajanja telesne dejavnosti).
Why has Adcirca been approved? 
Zakaj je bilo zdravilo Adcirca odobreno?
The active substance in Adcirca, tadalafil, belongs to a group of medicines called ‘phosphodiesterase type 5 (PDE5) inhibitors', which means that it blocks the PDE5 enzyme. 
Zdravilna učinkovina v zdravilu Adcirca, tadalafil, spada v skupino zdravil, imenovanih zaviralci fosfodiesteraze tipa 5 (PDE5), kar pomeni, da zavira encim PDE5.
Adcirca must not be used in patients who have had an acute myocardial infarction (sudden heart attack) within the last three months, or who have severe hypotension (low blood pressure). 
Zdravilo se ne sme se uporabljati pri bolnikih, ki so v zadnjih treh mesecih doživeli akutni miokardni infarkt (nenaden srčni napad) ali ki imajo hudo hipotenzijo (nizek krvni tlak).
This pressure reduces the amount of oxygen that can get into the blood in the lungs, making physical activity more difficult. 
Povečan tlak zniža količino kisika, ki lahko pride v kri v pljučih, zaradi česar je telesna dejavnost otežena.
Patients with mild or moderate kidney or liver problems should start with a lower dose, but this can be increased if 
Bolniki z blagimi ali zmernimi težavami z ledvicami ali jetri naj začnejo zdravljenje z nižjim odmerkom, ki pa se po
Adcirca treatment should only be started and monitored by a doctor who has experience in the treatment of PAH. 
Zdravljenje z zdravilom Adcirca sme uvesti in nadzorovati le zdravnik, ki ima izkušnje z zdravljenjem pljučne arterijske hipertenzije.
Adcirca must not be taken with nitrates (a group of medicines used to treat angina) or medicines of the class ‘guanylate cyclase stimulators' such as riociguat (another medicine to treat pulmonary hypertension). 
Zdravilo Adcirca se ne sme jemati z nitrati (skupino zdravil za zdravljenje angine pektoris) ali z zdravili razreda spodbujevalcev gvanilat ciklaze, kot je riocigvat (drugo zdravilo za zdravljenje pljučne hipertenzije).
For the full list of all side effects and restrictions with Adcirca, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Adcirca glejte navodilo za uporabo.
Four doses of Adcirca (2.5, 10, 20 and 40 mg once a day) have been compared with placebo (a dummy treatment) in one main study involving 406 patients with PAH, most of whom had class II or class III disease that was of unknown cause or caused by collagen vascular disease. 
Štiri odmerke zdravila Adcirca (2,5, 10, 20 in 40 mg enkrat na dan) so primerjali s placebom (zdravilom brez zdravilne učinkovine) v eni glavni študiji, v katero je bilo vključenih 406 bolnikov s pljučno arterijsko hipertenzijo.
It must not be used in patients who have ever had loss of vision because of a problem called nonarteritic anterior ischaemic optic neuropathy (NAION) that affects the blood flow to the nerve in the eye. 
Zdravilo se ne sme uporabljati pri bolnikih, ki so v preteklosti izgubili vid zaradi nearteritične anteriorne ishemične optične nevropatije (NAION), ki vpliva na dotok krvi v očesni živec.
In patients with PAH, Adcirca widens the blood vessels of the lungs, which lowers the blood pressure and improves symptoms. 
Pri bolnikih s pljučno arterijsko hipertenzijo zdravilo Adcirca razširi krvne žile v pljučih, kar zmanjša krvni tlak in izboljša simptome.
Adcirca has been shown to be effective in PAH with no identified cause and in PAH caused by collagen vascular disease. 
Zdravilo Adcirca se je izkazalo za učinkovito pri pljučni hipertenziji brez opredeljenega vzroka in pri pljučni hipertenziji, katere vzrok je sistemska bolezen veziva.
It causes high blood pressure in the vessels taking blood from the heart to the lungs. 
To povzroči zelo visok krvni tlak v žilah, po katerih se kri pretaka iz srca v pljuča.
How has Adcirca been studied? 
Kako je bilo zdravilo Adcirca raziskano?
What is Adcirca used for? 
Za kaj se zdravilo Adcirca uporablja?
How is Adcirca used? 
Kako se zdravilo Adcirca uporablja?
What is Adcirca? 
Kaj je zdravilo Adcirca?
How does Adcirca work? 
Kako zdravilo Adcirca deluje?
Under these conditions the ability to react may be decreased. 
V takih pogojih je zmožnost reagiranja lahko zmanjšana.
Rare (0.01-0.1%) 
Redki (0,01-0,1 %)
Common (>1%) 
Pogosti (> 1 %)
This should be taken into account when driving or using machines. 
Pri vožnji in uporabi strojev je treba to upoštevati.
Titanium dioxide (E 171) 
Titanov dioksid (E 171)
(see section 4.8 Undesirable effects). 
(glejte poglavje 4.8 Neželeni učinki).
Aluminium/Aluminium blister (Alu/OPA/PVC/PE) 
Pretisni omot iz aluminija/aluminija (Alu/OPA/PVC/PE)
However, in order to avoid treatment failure, local antibacterial resistance patterns and local guidelines should be considered. 
Za preprečitev neuspešnega zdravljenja je treba upoštevati lokalne vzorce antibakterijske rezistence in lokalne smernice.
Consideration should be given to official local guidance (e.g. national recommendations) regarding bacterial resistance and the appropriate use and prescription of antibacterial agents. 
Bodite pozorni na uradne smernice (npr. državna priporočila) glede bakterijske rezistence in ustrezne uporabe ter predpisovanja antibakterijskih sredstev.
Each hard capsule contains 15 or 30 mg lansoprazole. 
Vsaka trda kapsula vsebuje 15 ali 30 mg lansoprazola.
The capsules may be emptied, but the contents may not be chewed or ground. 
Kapsule se lahko izpraznijo, vendar se njihove vsebine ne sme žvečiti ali zdrobiti.
dry mouth or throat, 
suha usta ali žrelo,
Because of limited safety data for patients on maintenance treatment for longer than 1 year, regular review of the treatment and a thorough benefit risk assessment should regularly be performed in these patients (see “5.3 Preclinical safety data”). 
Zaradi omejenih podatkov o varnosti bolnikov na vzdrževalnem zdravljenju, ki traja dlje kot eno leto, je treba redno ocenjevati zdravljenje in opraviti temeljito oceno tveganja in koristi (glejte 5.3 Predklinični podatki o varnosti).
Interaction with Other Medicinal Products and Other Forms of Interaction 
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
7, 10, 14, 15, 20, 28, 30, 35, 50, 56, 60, 84, 98, 100 and 250 capsules 
7, 10, 14, 15, 20, 28, 30, 35, 50, 56, 60, 84, 98, 100 in 250 kapsul
If visual disturbances occur during long-term use (>1 year), an ophthalmologist should be consulted. 
Če se pri dolgotrajni uporabi (> 1 leto) pojavijo motnje vida, se je treba posvetovati z okulistom.
2, 7, 10, 14, 15, 20, 28, 30, 35, 42, 50, 56, 60, 98, 100 and 250 capsules 
2, 7, 10, 14, 15, 20, 28, 30, 35, 42, 50, 56, 60, 98, 100 in 250 kapsul
Bioavailability after a single dose of 30 mg and after repeated daily administration is 80-90%. 
Biološka razpoložljivost po enkratnem 30-miligramskem odmerku in po ponavljajoči se dnevni uporabi je 80-90 %.
The dose should be individually adjusted and the treatment should be continued for as long as necessary. 
Odmerek je treba prilagoditi vsakemu bolniku posebej in zdravljenje nadaljevati, dokler je potrebno.
15 mg once daily. 
15 mg enkrat dnevno.
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANT, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 
DODATEK I SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, NAČINOV UPORABE ZDRAVILA, VLAGATELJEV, IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH ČLANICAH
Eradication of Helicobacter pylori: 
Eradikacija Helicobacter pylori:
Preliminary data suggest that lansoprazole-based eradication therapy is effective in children and the elderly. 
Predhodni podatki nakazujejo, da je eradikacijsko zdravljenje na osnovi lansoprazola učinkovito pri otrocih in starostnikih.
Lansoprazole is not recommended in children as safety and efficacy have not been established in this population. 
Uporabo lansoprazola pri otrocih odsvetujemo, saj njegova varnost in učinkovitost v tej populaciji še ni ugotovljena.
Undesirable Effects 
Neželeni učinki).
Elderly: Due to delayed elimination of lansoprazole in the elderly it may be necessary to administer the treatment in doses of 15-30 mg adjusted to individual requirements. 
Starejše osebe: Zaradi podaljšanega izločanja lansoprazola, bo pri starejših osebah morda treba zdravljenje razdeliti v odmerke po 15-30 mg, glede na potrebe posameznika.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. 
Bolniki z redkimi podedovanimi težavami z netoleranco za fruktozo, okvarjeno absorpcijo glukoze in galaktoze ali pomanjkanjem sukraze-izomaltaze ne smejo jemati tega zdravila.
Intake of food slows the absorption rate of lansoprazole and reduces its bioavailability (AUC) by about 25%. 
Uživanje hrane upočasni absorpcijo lansoprazola in zmanjša biološko razpoložljivost (AUC) za približno 25 %.
30 mg lansoprazole 2 times daily for one week in combination with one of the following three combinations: 
30 mg lansoprazola dvakrat dnevno v trajanju enega tedna v kombinaciji z eno od treh navedenih kombinacij:
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, 
Študije na živalih ne kažejo neposrednih ali posrednih škodljivih vplivov na nosečnost, razvoj zarodka/plodu, porod ali postnatalni razvoj.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with lansoprazole should be made taking into account the benefit of breast feeding to the child and the benefit of lansoprazole therapy to the woman. 
Pri odločitvi, ali nadaljevati ali prekiniti dojenje oziroma ali nadaljevati ali prekiniti zdravljenje z lansoprazolom, je treba upoštevati korist dojenja za otroka in korist zdravljenja z lansoprazolom za žensko.
ANNEX III AMENDED SUMMARY OF PRODUCT CHARACTERISTICS OF THE REFERENCE MEMBER STATE 
DODATEK III SPREMENJEN POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA REFERENČNE DRŽAVE ČLANICE
CYP2C19 is subject to genetic polymorphism and 2-6% of the population, called poor metabolisers (PMs), are homozygote for a mutant CYP2C19 allele and therefore lacks a functional CYP2C19 enzyme. 
CYP2C19 je izpostavljen genetskemu polimorfizmu in 2-6 % populacije, t. i. slabi presnavljalci (PM - Poor Metaboliser), so homozigoti za mutantni alel CYP2C19, in zato nimajo funkcionalnega encima CYP2C19.
Reflux oesophagitis may not present as ulceration and/or visual damage, therefore in certain cases endoscopy alone may not be sufficient. 
Refluksni ezofagitis morda ni prisoten v obliki razjede in/ali vidne poškodbe, zato v nekaterih primerih endoskopija ni zadostna.
Note: This SPC is the one that was Annexed to the Commission Decision on this Article 29 referral for lansoprazole containing medicinal products. 
Opomba: Ta Povzetek glavnih značilnosti zdravila je bil priložen k odločbi Komisije v zvezi s tem postopkom, ki je bil sprožen v skladu s členom 29, za zdravila, ki vsebujejo lansoprazol.
Very Rare 
Zelo redki (<
Pharmacotherapeutic group: Proton pump inhibitors, ATC code: A02BC03. 
Farmakoterapevtska skupina: Zaviralci protonske črpalke, oznaka ATC: A02BC03.
The plasma protein binding of lansoprazole is about 95%, but this has not been found to have a significant effect on other protein bound drugs. 
Vezava lansoprazola na beljakovine v plazmi je približno 95-odstotna, vendar to ne vpliva na druga zdravila, ki se vežejo na beljakovine v plazmi.
It may not be excluded that lanzoprazole may affect transport via this protein giving rise to increased plasma concentrations of P-gp substrates such as digoxin. 
Ni mogoče izključiti možnosti, da lansoprazol morda vpliva na transport prek te beljakovine in posledično poveča plazemske koncentracije substratov P-gp, kot je digoksin.
The risk/benefit ratio of Lansopon 15 mg, 30 mg is considered to be favourable provided that appropriate information regarding H. pylori eradication therapy are included in the SPC. 
Razmerje med tveganji in koristmi zdravila Lansopon 15 mg, 30 mg velja za ugodno pod pogojem, da se ustrezni podatki v zvezi z eradikacijskim zdravljenjem H. pylori vključijo v Povzetek glavnih značilnosti zdravila.
petechia, purpura, hair loss, erythema multiforme, stevens 
petehija, purpura, izguba las, multiformni eritem,
The intake of food reduces the bioavailability of lansoprazole: it is recommended to take lansoprazole before the meal. 
Uživanje hrane zmanjša biološko razpoložljivost lansoprazola: lansoprazol je priporočeno vzeti pred obrokom.
palpitation and chest pain. 
palpitacije in bolečine v prsnem košu.
Lansoprazole is concentrated in the parietal cells and becomes active in their acidic environment, whereupon it reacts with the sulphydryl group of H 
Lansoprazol je koncentriran v parietalnih celicah in se aktivira v njihovem kislem okolju, kjer reagira s sulfidrilno skupino H +/K
The effects of other drugs on lansoprazole 
Učinek drugih zdravil na lansoprazol
Endocrine disorders gynecomastia, galactorrhoea. 
Bolezni endokrinega sistema ginekomastija, galaktoreja.
Concomitantly taken food slows down and reduces the absorption of lansoprazole. 
Sočasno uživanje hrane upočasni in zmanjša absorpcijo lansoprazola.
*The effects of clarithromycin on the pharmacokinetics of lansoprazole are likely to be dependent on the patient's CYP2C19 genotype. 
*Učinki klaritromicina na farmakokinetiko lansoprazola so verjetno odvisni od bolnikovega genotipa CYP2C19.
Johnson syndrome and toxic epidermal necrolysis. 
Stevens-Johnsonov sindrom in toksična epidermalna nekroliza.
Clinically significant interactions of lansoprazole with nonsteroidal anti-inflammatory drugs or diazepam have not been demonstrated, though formal interaction studies with lansoprazole and NSAIDs have not been conducted. 
Klinično pomembnih interakcij med lansoprazolom in nesteroidnimi protivnetnimi zdravili ali diazepamom niso opazili, vendar formalnih študij interakcij med lansoprazolom in nesteroidnimi protivnetnimi zdravili niso opravili.
Combinations of lansoprazole with one or two antibiotics produced equivalent eradication of H. pylori. 
S kombinacijo lansoprazola z enim ali dvema antibiotikoma so dosegli enakovredno eradikacijo H. pylori.
Member State Marketing Authorisation 
Država članica Imetnik dovoljenja za promet z zdravilom
Results of studies on carcinogenic potential show that lansoprazole therapy is associated with Leydig cell hyperplasia and benign Leydig cell tumours in rats. 
Rezultati študij karcinogenega potenciala so pokazali, da je zdravljenje z lansoprazolom povezano s hiperplazijo Leydigovih celic in benignimi tumorji Leydigovih celic pri podganah.
The drug combination may result in increased carbamazepin concentrations as well as reduced lansoprazole concentrations. 
Ta kombinacija zdravil lahko povzroči povečanje koncentracije karbamazepina in zmanjšanje koncentracije lansoprazola.